MOORESTOWN, N.J., March 13, 2018 -- Tabula Rasa HealthCare, Inc., (“TRHC”) (NASDAQ:TRHC) announced today that Chief Pharmacotherapy Officer Robert L. Alesiani, PharmD, BCGP, has been named the 2018 Hugo H. Schaefer Award winner by the American Pharmacists Association (APhA).
The APhA Board of Trustees selected Dr. Alesiani for this award based on his outstanding contributions to the APhA, the profession of pharmacy, and society. The awards and honors program at APhA is the most comprehensive and prestigious within the profession.
“It is truly an honor to be chosen by APhA for the Hugo H. Schaefer Award,” said Dr. Alesiani. “I look forward to continuing to improve patients’ lives, to help to hone the skills of our next generation of clinicians, and to make a positive impact in the profession. The future of pharmacy is bright!”
As Chief Pharmacotherapy Officer, Dr. Alesiani leads the Clinical Team at CareKinesis, a Tabula Rasa HealthCare company. He is one of the first clinical pharmacists in the U.S. with expertise to provide precision medicine, in particular, pharmacogenomic testing coordination and translation for people on high-risk medications. A Board-Certified Geriatric Pharmacist (BCGP), he has extensive knowledge in the field of geriatric pharmaceutical care, and he has guided his entire team of eligible pharmacists to 100% BCGP certification.
“Dr. Alesiani and I have worked together for decades,” stated Calvin H. Knowlton, PhD, Chairman, CEO and Founder of Tabula Rasa HealthCare. “Bob always has been in the vanguard of pharmacy and pharmaceutical care. He has a tremendous knowledge and experience in hospice and palliative care. He endlessly dedicates himself to bettering society through his practice. I believe he is more than deserving of this award.”
The award will be presented to Dr. Alesiani at the APhA Annual Meeting and Exposition in Nashville, Tennessee, March 16-19, 2018.
Dr. Alesiani received a BS in Marine Sciences from The Richard Stockton University (1979) in New Jersey, a BPharm from the University of the Sciences in Philadelphia (1987) and his PharmD from the University of Florida (2005), where he graduated cum laude and received the Outstanding Graduating Clinician Award. He returned in 2016 to complete a certification in Pharmacogenomic Translation and Application.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, visit: www.TRHC.com.
Contact
Dianne Semingson
[email protected]
T: 215-870-0829


Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Jetstar to Charge for Overhead Cabin Bags From February
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
DeepSeek to Raise AI API Prices as Demand for New Models Surges 



